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Abstract
Background: Current treatments for Alzheimer’s disease and related disorders (ADRD) are symptomatic and can
only temporarily slow down ADRD. Future possibilities of care rely on multi-target drugs therapies that address
simultaneously several pathophysiological processes leading to neurodegeneration. We hypothesized that the
combination of memantine with vitamin D could be neuroprotective in ADRD, thereby limiting neuronal loss and
cognitive decline. The aim of this trial is to compare the effect after 24 weeks of the oral intake of vitamin D3
(cholecalciferol) with the effect of a placebo on the change of cognitive performance in patients suffering from
moderate ADRD and receiving memantine.
Methods: The AD-IDEA Trial is a unicentre, double-blind, randomized, placebo-controlled, intent-to-treat, superiority
trial. Patients aged 60 years and older presenting with moderate ADRD (i.e., Mini-Mental State Examination [MMSE]
score between 10-20), hypovitaminosis D (i.e., serum 25-hydroxyvitamin D [25OHD] < 30 ng/mL), normocalcemia (i.
e., serum calcium < 2.65 mmol/L) and receiving no antidementia treatment at time of inclusion are being
recruited. All participants receive memantine 20 mg once daily -titrated in 5 mg increments over 4 weeks- and
each one is randomized to one of the two treatment options: either cholecalciferol (one 100,000 IU drinking vial
every 4 weeks) or placebo (administered at the same pace). One hundred and twenty participants are being
recruited and treatment continues for 24 weeks. Primary outcome measure is change in cognitive performance
using Alzheimer’s Disease Assessment Scale-cognition score. Secondary outcomes are changes in other cognitive
scores (MMSE, Frontal Assessment Battery, Trail Making Test parts A and B), change in functional performance
(Activities of Daily Living scale, and 4-item Instrumental Activities of Daily Living scale), posture and gait (Timed Up
& Go, Five Time Sit-to-Stand, spatio-temporal analysis of walking), as well as the between-groups comparison of
compliance to treatment and tolerance. These outcomes are assessed at baseline, 12 and 24 weeks, together with
the serum concentrations of 25OHD, calcium and parathyroid hormone.
Discussion: The combination of memantine plus vitamin D may represent a new multi-target therapeutic class for
the treatment of ADRD. The AD-IDEA Trial seeks to provide evidence on its efficacy in limiting cognitive and
functional declines in ADRD.
Trial Registration: ClinicalTrials.gov number, NCT01409694
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Alzheimer’s disease (AD) is the leading cause of dementia
and loss of autonomy and independency in the elderly
[1,2]. AD is characterized by a progressive decline of cog-
nitive performance with a deleterious impact on social
activities. The magnitude of this problem will increase
over the next decades due to the demographic shift of the
aging population. In order to mitigate and delay AD-
related adverse effects, the development of new effective
therapeutic strategies is essential [1,2].
In addition to a decrease in brain cholinergic activity
that justifies the use of acetylcholinesterase inhibitors [1],
AD is also marked by glutamatergic excitotoxicity [3,4]
that results in neuronal death through two distinct
mechanisms: immediate neuronal necrosis in the case of
excessive intraneuronal calcium influx, and delayed neuro-
nal apoptosis in the case of moderately excessive calcium
influx with subsequent oxidative stress [5,6]. The clinical
consequence of these chain reactions for glutamatergic
neurons is the loss of learning and memory abilities char-
acterizing dementia syndromes including AD and related
disorders (ADRD) [1,3,4].
These pathophysiologic mechanisms explain why one
of the most prescribed drugs to slow the progression of
ADRD is memantine; a voltage-dependent, low-affinity,
noncompetitive N-methyl-D-aspartate (NMDA) receptor
antagonist [7,8]. The effectiveness of this drug was estab-
lished in double-blind placebo-controlled trials in moder-
ate to severe stages of dementia. Memantine has no
immediate treatment effect, but after 3 to 6 months of
use, patients report better cognitive performance and
autonomy than those receiving placebo [7,8]. However,
symptom improvement is transient and the memory
scores then adopt a similar course to those in the placebo
group [9]. Indeed, the use of memantine may result in
the protection of glutamatergic neurons associated with
the avoidance of neuronal necrosis phenomena subse-
quent to the excessive and prolonged influx of calcium
into the cell, but AD patients using memantine are still
exposed to oxidative stress and neuronal apoptosis. Thus,
while NMDA receptor antagonists such as memantine
allow symptomatic treatment of AD by temporarily slow-
ing disease progression, they do not allow a preventive or
curative treatment [7,8]. Coupling an antioxidant with
memantine could therefore provide a solution to the pro-
blem of neuronal apoptosis induced by glutamatergic
excitotoxicity.
Vitamin D is a neurosteroid hormone which crosses
the blood-brain barrier and binds to vitamin D receptors
(VDR) present in neurons and glial cells of the central
nervous system including the hippocampus, the
hypothalamus, the cortex and the subcortex [10-12].
More precisely, 1.25-dihydroxyvitamin D (active form of
vitamin D) regulates the intra-neuronal calcium home-
ostasis via the regulation of voltage-gated calcium chan-
nels - thus preventing necrosis - [13], and has also
exhibited neuroprotective properties against glutamate
toxicity through antioxidant effects - thus preventing
apoptosis. This antioxidant action was described in 2001
in cultures of rat mesencephalic cells [14]. This is parti-
cularly important in that over 70% of adults aged 75
and over are deficient in vitamin D [15,16] and should
receive vitamin D supplementation, and especially since
vitamin D deficiency has been associated with cognitive
decline [10,17-20]. Thus, based on the neurosteroid
properties of vitamin D, it can be argued that the cor-
rection of hypovitaminosis D may be protective against
cognitive decline [11,20-23]. For illustration, it has
already been shown that high exogenous supplies of
vitamin D were associated with better cognitive perfor-
mance compared to lower supplies [21,22]. What is
more, it is interesting to note that the actions of vitamin
D on the nervous system seem to be complementary
and perfectly suited to those of memantine, and there is
no reason to expect a deleterious interaction of these
molecules [11].
Finally, the known actions of both these molecules are
not reduced to learning and memory, but also improves
physical performance. Indeed, each molecule taken sepa-
rately has already been associated with an improvement of
gait [24-26]. This is especially important since one of the
main complication of ADRD relies on motor dysfunction
illustrated by chronic gait disorders and loss of functional
independence [2,27]. The expected improvement of cogni-
tive performance in ADRD patients receiving both mem-
antine and vitamin D could thus be accompanied by
improved posture and gait performance.
We hypothesized that the combination of memantine
plus vitamin D could be more protective in ADRD than
taking memantine alone against the neuronal loss and the
subsequent declines in cognitive and gait performance.
Objectives
Primary objective
The primary objective is to compare the effect after
24 weeks of the oral intake of vitamin D3 with the effect
of a placebo on the evolution of cognitive performance
in patients suffering from moderate ADRD and receiv-
ing memantine.
Secondary objectives
The secondary objectives of the study are as follows:
- To compare the effect after 12 weeks of the oral
intake of vitamin D3 with the effect of a placebo on the
evolution of cognitive performance in patients suffering
from moderate ADRD and receiving memantine.
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oral intake of vitamin D3 with the effect of a placebo on
the evolution of functional abilities in patients suffering
from moderate ADRD and receiving memantine.
- To compare the effect after 12 and 24 weeks of the
oral intake of vitamin D3 with the effect of a placebo on
the evolution of postural and gait performance in
patients suffering from moderate ADRD and receiving
memantine.
- To determine the compliance to treatment and tol-
erancy of the oral intake of vitamin D3 in patients suf-
fering from moderate ADRD and receiving memantine.
Methods
Design
This is a unicentre, double-blind (with patient, carer,
clinician, outcome assessor and investigators blinded),
randomized, placebo-controlled, parallel group, intent-
to-treat, superiority clinical trial. Figure 1 illustrates the
trial design and Table 1 summarizes the timing of the
trial. All participants receive trial interventions for 24
weeks as recommended by the European Medicines
Agency (EMEA) guidelines [28]. The randomization is
stratified depending on the nature of dementia (i.e.,
Alzheimer’s disease [AD], or related disorders [RD]).
Thus, for each stratum (2 strata), a distinct randomiza-
tion list is established by the Clinical Research Centre
(CRC) of Angers with the use of the N’Query randomiza-
tion software. In order to best limit potential imbalances,
a block randomization is used.
Randomization lists were transmitted to the central
pharmacy of Angers University Hospital which is in charge
of assigning the ‘patients’ kits’ in compliance with the ran-
domization lists, and of shipping the kits containing con-
taining all the medicines for the duration of the study (i.e.,
322 tablets of memantine 10 mg, and 6 × 100,000 IU cho-
lecalciferol or placebo vials) to the memory centre of
Angers University Hospital. Of these 322 tablets of mem-
antine, 316 are theoretically used during the 24-week fol-
low-up, and an additional 6 tablets (equivalent to 3 days
treatment) were added in each kit to be more flexible in
determining the date of the final visit.
- ‘Intervention’ group
All participants start the treatment with memantine
(Lundbeck Laboratory, Issy-les-Moulineaux, France) on
t h ef i r s td a yo ft h es t u d y .M e mantine is administered
according to the usual strategy, with upward titration of
5 mg per week during the first four weeks to reduce the
risk of side effects. The final dosage is 20 mg per day,
with no subsequent modification of dosage or specialty
during the trial. In parallel, the participants of this
group immediately commence vitamin D supplementa-
tion (cholecalciferol 100,000 IU [Crinex Laboratory,
Montrouge, France], drinking solution, 2 mL vial) at a
rate of 1 drinking vial of 100,000 IU cholecalciferol every
month. In brief, the total dose is 600,000 IU over the
study period of 168 days, starting with one vial at the
time of inclusion, then at Week (W) 4, W8, W12, W16
and W20. It is generally recognized that each additional
100 IU of vitamin D per day raises serum 25OHD con-
centration by 0.7 ng/mL [29]. The daily dose of 3,571 IU
in the AD-IDEA trial is thus expected to raise the serum
25OHD concentration by at least 25 ng/mL, with a con-
centration ultimately reached > 30 ng/mL. This is all the
more important in that, based on the knowledge of vita-
min D effects in organs other than brain, it seems that
raising serum 25OHD concentrations above 30 ng/mL is
necessary to obtain an effect on non-skeletal targets [30].
We assume that the 24 week assessment will capture a
treatment effect since vitamin D supplementation > 6
months is not more effective than shorter treatment ≤ 6
months for the prevention of non-skeletal adverse events
[31]. Finally, it has to be quoted that the chosen dose of
3,571 IU per day does not reach toxic doses (i.e., 10,000
IU per day) and raises vitamin D concentrations within
non-toxic limits (i.e., 150 ng/mL) [32]. As a consequence,
the dose of vitamin D supplementation will not be
adjusted except in the case of a serious adverse event
such as hypercalcemia, possibly resulting from the intest-
inal absorption of dietary calcium under the action of
vitamin D [16,30]. In this case, vitamin D supplementa-
tion is stopped and the participant is released prema-
turely from the study.
- ‘Placebo’ group
Participants in this arm start the treatment with mem-
antine at the same rate as the ‘Intervention’ group. They
also immediately start cholecalciferol placebo (Placebo
[Crinex Laboratory, Montrouge, France], drinking solu-
tion, 2 mL vial) administered at the same pace (i.e., W0,
W4, W8, W12, W16 and W20). The placebo drinking
solution contains all the excipients present in the chole-
calciferol vial and is not distinguishable from the active
product (vitamin D).
Regardless of groups, enrolled participants are also
provided with oral and written information that they
cannot, in any case, be prescribed medication containing
vitamin D or memantine or acetylcholinesterase inhibi-
tors outside of the trial for the duration of the study.
Planned eligibility criteria
Pre-inclusion criteria
People are considered for possible inclusion if they are
aged 60 years and older, meet the DMS-IV criteria for
dementia [33] at a moderate stage (MMSE score
between 10 and 20 inclusively) [34] and are affiliated to
French Social Security.
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People are eligible to participate if they meet the
National Institute of Neurological and Communicative
Disorders and Stroke/Alzheimer’s Disease and Related
Disorders Association (NINCDS/ADRDA) criteria [35],
have hypovitaminosis D (i.e., serum 25-hydroxyvitamin
D [25OHD] concentration ≤30 ng/mL) [36] and no
hypercalcemia (i.e., serum calcium concentration < 2,65
mmol/L). Participants must also have given and signed
an informed consent form to participate in the trial (or
Figure 1 Trial flow chart. Flow chart of the Trial Study.
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Page 4 of 10Table 1 Calendar summary
Period Pre-selection Inclusion Follow-up End of the study
Week (W) W0 W12 W24
Pre-inclusion criteria X
Inclusion/Non-inclusion criteria X
Informed consent X
Inclusion clinical examination X
Analysis of posture and gait XX X
Assigning a ‘Patient’s kit’according to inclusion number in compliance with randomization lists X
Serum 25OHD measurement XX X
Serum calcium measurement XX X
Serum parathyroid hormone measurement X X X
Treatment administration X
Compliance (account of fully consumed vials) XX
Follow-up clinical examination XX
Cognitive scores (including ADAS-cog) X X X
Functional scores XX X
AEs and SAEs XX X
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son or legal representative, as appropriate).
Non-inclusion criteria
The following non-inclusion criteria are considered:
severe, unstable or poorly controlled medical conditions
apparent from physical examination or clinical history,
severe hepatic or renal failure, the use of standard antide-
mentia drugs (i.e., acetylcholinesterase inhibitors, meman-
tine, or vasodilatators) in the past 60 days, other cognitive
disorders (untreated dysthyroidy, deficiency in vitamin B9
or B12, alcohol-related dementia, history of syphilis or of
strategic stroke, delirium at time of inclusion [Confusion
Assessment Method positive] [37], presence of severe
depressive symptoms [15-item Geriatric Depression Scale
score ≥ 10]) [38], contra-indications to memantine or vita-
min D including granulomatosis, and enrolment in
another simultaneous clinical trial.
Recruitment/consent procedures
Participants are identified from patients with ADRD meet-
ing study pre-inclusion criteria who are being followed up
in Angers University Memory Centre and other compo-
nents of specialist mental health, geriatric medicine or
neurology services. Once a potential participant is identi-
fied and meets the eligibility criteria, the investigating phy-
sician provides the patient (as well as a family member, a
trusted person or a legal representative, as appropriate)
w r i t t e na n do r a li n f o r m a t i o no nt h es t u d yi na nu n d e r -
standable language, and obtains written consent to take
part in the study in line with the trial standard operating
procedures. When possible, fully informed consent is
obtained from the patient. When ADRD patient is unable
to give fully informed consent, agreement to participate in
the study is obtained from the trusted person or from the
legal representative, as appropriate, and the patient is not
enrolled if s/he refuses or shows significant distress. If
neither is available to consent, the patient is ineligible for
the study. In case of non-inclusion (if the patient does not
meet the above selection criteria) or refusal to participate
in the study, the investigating physician will record the
existence or absence of selection criteria and the causes of
non-participation in the study, and copy them in the “Reg-
istry of non-eligible and eligible patients”.
Assessments
Study assessment measures will be applied at baseline
prior to randomization, at W12 and at W24. All measures
in the study are already carried out systematically in every
patient admitted to Angers University Memory Centre.
Experience has shown that this mode of operation is feasi-
ble and appreciated by patients and their families, and has
never caused a breakdown in care so far. For this reason,
the large number of measures is not expected to exacer-
bate the loss to follow-up. To ensure adherence to the
intervention, nurses are prescribed for all participants to
administer medications safely and effectively. In addition,
phone calls are planned to keep in touch with the partici-
pant and to recall the date of follow-up visits. Trial com-
pletion is defined as completion of 24 weeks on the trial
medication or discontinuation of follow-up for any cause.
Participants who discontinue taking the trial medications
are encouraged to remain in follow-up. Arrangements for
continued provision of the trial medication at the end of
the trial is made on an individual basis thanks to a centra-
lized serum 25OHD measurement at W24 which allows
the investigating physician in charge of the patient making
rapid and appropriate decisions regarding carrying on,
modifying or discontinuing vitamin D supplementation at
the end of the study.
Primary Outcome Measure
-A l z h e i m e r ’s Disease Assessment Scale-cognition
(ADAS-cog) score The ADAS-cog [39] is a well-estab-
lished measure of cognitive fu n c t i o ni no l d e ra d u l t s .I t
shows good test-retest and inter-rater reliability and per-
forms satisfactorily against more detailed measures of cog-
nitive function. Score range varies from 0 to 70. The more
mistakes, the higher the score is. A normal score is defined
as a score lower than 10. A 70-point score is a sign of
severe dementia. A variation of at least 3 points during the
study is considered as clinically relevant [40].
Secondary Outcomes Measures
- Mini-Mental State Examination (MMSE) score The
MMSE [41] is used to assess cognitive funtions and mne-
sic abilities. The test consists in a series of 30 questions
composed of five sections (orientation, registration, atten-
tion-calculation, recall, and language), with final score
graded out of 30 points. A final score below or equal to 25
points corresponds to a dementia diagnosis. A score
between 25 and 21 indicates mild dementia. A score
between 20 and 10 indicates moderate dementia. A score
below 10 indicates severe dementia [34]. A variation of 2
points during the study is considered as clinically relevant
[42].
- Frontal Assessment Battery (FAB) score The FAB
explores executive functions [43]. It consists of 6 subtests
marked on 3 points with a total score of 18. A score under
14 is abnormal [43]. The matching task explores concep-
tual elaboration; the verbal fluency task explores lexical
evocation and mental shifting; the search for prehension
behavior explores environmental autonomy; Luria’s motor
sequences explore programming abilities; the conflicting
instructions tasks explore sensitivity to interference;
finally, the Go/No Go task explores motor inhibition.
- Trail Making Test (TMT) parts A and B score The
TMT [44] assesses mental shifting and consists of two
parts. First, the subject is required to draw lines to connect
numbers in ascending order as quickly as possible. This
part (TMT A) assesses visual perception rapidity and
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mental shifting and the subject’s attention ability since s/
he is required to do the same as for TMT A, but alternat-
ing between numbers and letters. The subject is asked to
perform the task as quickly as possible without lifting his/
her pen. If the experimentor sees a mistake, s/he tells the
patient. The following items are recorded: time spent (part
A, part B; difference between time spent for parts A and
B), and the number of errors (total number of errors parts
A and B; perseverant errors for part B; difference in num-
ber of errors in parts A and B). If the time to complete
TMT B is longer than 240 seconds, then the test is
stopped and the number of figures connected in the
allotted time as well as the number of errors is noted.
- Activities of Daily Living scale (ADL) score The
patient’s ability to perform the main activities of daily liv-
ing and to adapt to his/her environment is measured
thanks to this systemized questionnaire exploring activities
of body care, dressing, elimination and continence, mobi-
lity and eating [45]. The ability to perform an item is
worth 1 point. A maximum score of 6 out of 6 corre-
sponds to a state of independence. A score lower than 3
out of 6 defines a state of dependence.
- 4-item Instrumental Activities of Daily Living scale
(IADL-PAQUID) score The purpose of this screening test
is to assess behaviors and the use of common tools: using
transportation, managing finances, using the phone, mana-
ging medicines [46]. If one of these functions is affected, it
is marked 1. Disability starts from a score of 2 out of 4.
- Performed Timed “Up & Go” (TUG) and Imagined
Timed “Up & Go” (iTUG) The TUG assesses gait and
postural performance. The TUG is to measure time in sec-
onds used by a subject to rise from his chair, walk three
meters, turn around and return to the sitting position [47].
A time longer than 20 seconds is pathological. The iTUG
assesses motor imagery. It is to make TUG first, and then
to sit on the chair and imagine doing it again [48]. The
time taken by the subject to imagine the iTUG is mea-
sured in seconds. Age and cognitive decline are associated
with significantly increased TUG and decreased iTUG
[48].
- Five Time Sit-to-Stand test (FTSS) The FTSS measure
patient’s postural abilities. The test is to stand up from a
chair five times as quickly as possible without pushing off.
Performance is measured with a stopwatch in seconds, as
the time from the initial seated position to the final seated
position after completing five stands. A time longer than
15 seconds is abnormal and is associated with physical
and cognitive impairments [49].
- Spatio-temporal analysis of walking These para-
meters are measured using GAITRite
® system (972 cm
long, active electronic surface area 792 × 610 cm, with a
total of 29,952 pressure sensors, scanning frequency
60 Hz, software version 3.8, CIR System, Havertown, PA).
Participants walk in a quiet, well-lit room wearing their
own footwear according to European guidelines for spatio-
temporal gait analysis in older adults [50]. The walk tests
are performed consecutively with and without a concur-
rent attentional task [27].
- Compliance Empty, full or partially consumed vials and
tablets of memantine are stored by the subjects, brought
back to the investigating physician during each follow-up
consultation, and are counted in order to measure compli-
ance. In addition, the change of serum 25OHD concentra-
tion (including the correction of hypovitaminosis D) will
validate a posteriori the actual treatment intake within the
‘Intervention’ group.
- Blood samples collection procedures All subjects are
tested for 25OHD concentration at W0, and actually
included subjects are also tested at W12 and W24. Blood
sampling are done by a clinical research nurse at each con-
sultation. Serum 25OHD concentration is then measured
with the DiaSorin radioimmunoassay (RIA) kit (DiaSorin,
Stillwater, MN, USA) locally at the University Hospital at
Angers, France, to homogenize the measuring technique.
The RIA DiaSorin kit is the most used kit for such studies
and recognizes both D2 and D3. With this method, there is
no interference of lipids, which is often observed in other
non chromatographic assays of 25OHD. Additionally, this
method correlates with the reference method (high-perfor-
mance liquid chromatography with mass spectrometry
[HPLC-MS]). The intra- and interassay precisions are
respectively 5.2% and 11.3% (range in normal adults aged
20-60 yr, 30-125 ng/mL).
- Safety parameters The safety assessment parameters
are:
- Clinical: delirium, somnolence, asthenia, vertigo, head-
ache, epilepsy, nausea and vomiting, heart failure, lumbar
or right hypochondre pain in the case of biliary or renal
colics revealing calcic lithiasis (objectivized with echogra-
phy in the case of clinical suspicion), thrombosis (objecti-
vized with doppler in the case of clinical suspicion);
- Biological: serum calcium concentration. The serum
concentration of calcium is measured at baseline assess-
ment, then at W12 and W24 to monitor the occurrence of
hypercalcemia > 2,65 mmol/L [32]. The occurrence of
hypercalcemia leads to double-blind termination and pre-
mature withdrawal from the study, stops the vitamin D
supplementation and potential calcium supplements, and
triggers further complementary non-specific examinations
to find the cause of hypercalcemia for which vitamin D
intake could not be held responsible at first [16].
Statistics
Sample Size Calculation
The trial aims to recruit 120 patients over a period of 52
weeks. According to previous literature, we estimate that
the change in ADAS-cog score after 24 weeks in
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average [8]. In addition, it is usually considered in clini-
cal trials among AD patients that the minimum clini-
cally relevant change in ADAS-cog score is at least 3
points [40].
Thus, assuming a reference value of 1 and a variance of
25 (standard deviation estimated at 5), a two-sided test
w i t ha na l p h ar i s ko f5 % ,a n dap o w e r( 1-b e t a )o f9 9 % ,
t h es a m p l es i z et od e t e c ta3 - p o i n td i f f e r e n c ei nc h a n g e
from baseline in the ADAS-cog between the ‘Intervention’
group and the ‘Placebo’ group, is 52 subjects per group
(total 104 subjects).
Taking into account the loss to follow-up (estimated at
15%), it is necessary to include a total of 120 subjects (60
per group). This sample size has also adequate power (i.e.,
90%) to detect a smaller difference in ADAS-cog score (i.e.,
2 points). The sample size calculation also assumes
accounting for up to 12 covariables anticipating multivari-
ate analyses, including the change in comorbid conditions
possibly due to vitamin D supplementation [51] with sub-
sequent indirect cognitive benefits (using the Cumulative
Illness Rating Scale for Geriatrics [CIRS-G] score) [52], the
education level [1], the season tested [16], and the serum
concentrations of parathyroid hormone (PTH) and
calcium [53].
Analyses
The effect of vitamin D supplementation compared to pla-
cebo will be determined using evaluation criteria, which
are the changes in cognitive, functional and physical scores
between W0 and W12 and between W0 and W24, using
independent samples t-test or Mann-Whitney U test; and
the between-group comparisons of changes in cognitive,
functional and physical scores between W0 and W12, and
between W0 and W24, using an analysis of covariance.
Any exploratory analyses here will use multivariate logis-
tic and proportional hazards regression. In addition, the
stratification criterion for randomization (i.e., the nature of
dementia: AD or RD) will be also taken into account in the
multivariate models. Excessive subgroup analyses can give
rise to misleading results and therefore all subgroup investi-
gations will be interpreted cautiously. In particular, sub-
group analysis will be conducted depending on the severity
of hypovitaminosis D at the beginning of the study (i.e.,
serum 25OHD concentration below or above 10 ng/mL)
and on the severity of dementia at the beginning of the
study (i.e., MMSE score below or above 15). Finally, special
attention will be paid to participants that, while having
hypovitaminosis D at the beginning, did not show high
levels of PTH, to determine whether this group differenti-
ates of the PTH responders in terms of therapeutic benefits.
Ethical considerations
The protocol received Angers Research Ethics Commit-
tee approval, and was approved by the AFSSAPS
(French health products safety agency). The trial is con-
ducted in compliance with the European Union Clinical
Trials Directive (2001/20/EC), the French National
Commission for Information Technology and Freedom
(1978), the Public Health Code of Ethics, the Interna-
tional Conference on Harmonization guidelines for
Good Clinical Practice (CPMP/ICH/135/95), the princi-
ples of the Declaration of Helsinki (1996) and other
requirements as appropriate.
An Independent Data Monitoring Committee (IDMC)
will monitor the progress of the trial including: recruit-
ment, protocol adherence, serious adverse events and
side effects of treatment as well as the difference
between the trial treatments on the primary outcome
measures. The IDMC will produce a report to the Trial
Steering Committee (TSC) after every meeting and can
recommend premature closure of the trial following
clear evidence of benefit or harm in accordance with the
IDMC charter.
The main ethical issue here is related to the delay of
vitamin D supplementation in the ‘Placebo’ group. This
treatment delay of 24 weeks seems yet acceptable since
vitamin D supplementation has not yet proved efficient
for ADRD patients. Due to this reasonable doubt and to
the lack of standard treatments to be associated with
memantine, resorting to a placebo is thus conceivable
and justifies the study.
In addition, subject participating in this research can
also expect personal benefits. Individual expected bene-
fits are:
- All included subjects receive memantine, a standard
antidementia treatment that is appropriate for moderate
ADRD.
- For subjects within the ‘Intervention’ group, the
treatment will correct the hypovitaminosis D.
- Since presenting with hypovitaminosis D is an inclu-
sion criterion, participating in this study constitutes an
opportunity even for subjects receiving a placebo. Indeed,
in the hypothesis of an effectiveness of vitamin D, the sub-
jects in the ‘Placebo’ group would undergo a potential
transient loss of opportunity (i.e., being deficient and
receiving a placebo during the study period) balanced by
permanent growing opportunities at the end of the study
(i.e., receiving vitamin D supplementation).
- The expected benefits for the ‘Intervention’ group
are potentially important because, in the hypothesis of
an efficient action of the combination of memantine
plus vitamin D on brain, participation in this research
may prevent cognitive decline and improve ADRD
symptoms.
The expected collective benefits for this research are
an improvement of the knowledge of the non-skeletal
effects of vitamin D, and in particular of the cognitive
effects of the combination of vitamin D plus memantine.
Annweiler et al. Trials 2011, 12:230
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To date there is no curative treatment for ADRD and
existing symptomatic treatments only have a transient
efficacy.
The novel idea of combining memantine and vitamin D
is based on the supposed complementarity of their actions.
In particular, it appears that cognitive declines in AD and
hypovitaminosis D have a partially common pathophysio-
logical pathway based on the calcium neurotoxicity and
the alteration of protective mechanisms against glutama-
tergic excitotoxicity [11,20]. The use of vitamin D in
ADRD patients seems thus justified, particularly among
the deficient ones who are at least 70% of patients visiting
memory centres [15].
In addition to its neurosteroid “multi-target” effects,
testing vitamin D therapy sounds interesting in that
vitamin D can be associated with current antidementia
drugs as part of a “multi-drug” regimen [23]. This is an
important point when considering randomized con-
trolled trials since it seems almost impossible to get a
trial approved to examine the effectiveness of vitamin D
alone in ADRD patients after having removed standard
therapies. In addition, conducting a placebo-controlled
clinical trial in subjects with overt vitamin D deficiency
for a 6-month period is acceptable because of the
absence of expected accident linked to vitamin D defi-
ciency within this short period [23,54]. Despite all these
facilitating arguments and the growing interest in non-
skeletal effects of vitamin D [30], the AD-IDEA Trial is,
from the best of our knowledge, the first randomized
placebo-controlled trial on the effectiveness of vitamin
D in ADRD patients [23]. Its randomized double-blind
placebo-controlled design minimises the risk of bias.
Yet, generalization of the AD-IDEA findings will be lim-
ited by the single-centre design. The choice to conduct
t h et r i a li no n es i n g l em e m o r yc e n t r ew a se x p l a i n e db y
considerations of feasibility. If proven, the finding of an
effective response would prompt to extend the trial on a
variety of memory centers in several international hospi-
tals, with studied samples not restricted to senior
patients with moderate stages of dementia. Also, con-
ducting longer-term follow-up of 12 months and more
would provide additional information on the persistence
of the effect [28].
The combination of memantine plus vitamin D may
represent a new multi-target approach for ADRD. The
results of the AD-IDEA Trial will make a substantial
contribution to this new orientation of research, and in
all probability will provide clear evidence on the efficacy
of this new pharmaceutical composition in limiting cog-
nitive and functional declines in ADRD.
Trial status
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